Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Metformin (MET) is a diabetes drug that activates AMP‐activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AM...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cell Mol Med
Autores principales: Gao, Jun, Liu, Yang, Han, Gaijing, Deng, Kan, Liu, Xiaohai, Bao, Xinjie, Feng, Ming, Yao, Yong, Lian, Wei, Xing, Bing, Lv, Xiang, Wang, Renzhi
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237574/
https://ncbi.nlm.nih.gov/pubmed/30334324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13963
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares